Impact Biomedical (IBO) Non-Current Debt (2023 - 2025)

Impact Biomedical (IBO) has reported Non-Current Debt for 3 consecutive years, with $22.9 million the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Non-Current Debt rose 187.05% year-over-year to $22.9 million; the trailing twelve-month figure through Sep 2025 stood at $22.9 million (up 187.05% YoY), and the FY2024 full-year result was $12.1 million, changed 0.0% from the prior year.
• Non-Current Debt advanced to $22.9 million in Q3 2025 per IBO's latest filing, from $22.4 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $22.9 million in Q3 2025 and bottomed at $8.0 million in Q3 2024.
• Historically, Non-Current Debt has averaged $14.4 million across 3 years, with a median of $12.1 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Non-Current Debt changed 0.0% in 2024, then soared 187.05% in 2025.
• Over 3 years, Non-Current Debt stood at $12.1 million in 2023, then changed by 0.0% to $12.1 million in 2024, then jumped by 89.51% to $22.9 million in 2025.
• According to Business Quant data, Non-Current Debt over the past three periods registered $22.9 million, $22.4 million, and $9.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.